Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


arGentis Pharmaceuticals LLC

Latest From arGentis Pharmaceuticals LLC

arGentis acquires rights to rheumatoid arthritis therapy

The privately held biopharmaceutical company arGentis Pharmaceuticals is to collaborate with the University of Tennessee Health Science Center (UTHSC) and the Veterans Affairs Medical Center (VAMC) of Memphis to progress the oral altered peptide ligand (APL), ARG301, into a Phase I study in rheumatoid arthritis patients.

Orthopedics Immune Disorders
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Ophthalmic
  • Alias(es)
  • arGentis LLC
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • arGentis Pharmaceuticals LLC
  • Senior Management
  • Tom I Davis, Pres. & CEO
    J. Edward Townsend, VP, Bus. Dev.
  • Contact Info
  • arGentis Pharmaceuticals LLC
    Phone: (901) 818-3262
    1661 International Dr., Ste. 400
    Memphis, TN 38120